A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study

Neuro-Oncology

Volumn 17, Issue 6, 2015, Pages 854-861

  Schuster, James ^a   Lai, Rose K ^b,m   Recht, Lawrence D ^c   Reardon, David A ^d,n   Paleologos, Nina A ^e,o   Groves, Morris D ^f,p   Mrugala, Maciej M ^g   Jensen, Randy ^h   Baehring, Joachim M ⁱ   Sloan, Andrew ^j   Archer, Gary E ^d   Bigner, Darell D ^d   Cruickshank, Scott ^k   Green, Jennifer A ^l   Keler, Tibor ^l   Davis, Thomas A ^l   Heimberger, Amy B ^f   Sampson, John H ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Neurological Institute of Columbia University ^*  (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k Cruickshank and Associates   (United States)

^l Celldex Therapeutics Inc   (United Kingdom)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o RUSH UNIVERSITY MEDICAL CENTER   (United States)

^p TEXAS ONCOLOGY   (United States)

more..

Author keywords

ACT III; EGFRvIII; Glioblastoma; Glioma; Rindopepimut

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; RINDOPEPIMUT; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CANCER VACCINE; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; SUBUNIT VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ANTIBODY TITER; ARTICLE; ASTHENIA; CANCER IMMUNIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; VERY ELDERLY; ADJUVANT CHEMORADIOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84934981297     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou348     Document Type: Article

References (18)

1. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990;87(11):4207-4211.
2. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272(5):2927-2935.
3. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288-2294.
4. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962-6970.
5. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466.
6. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
7. Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24(16):1731-1745.
8. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619-624.
9. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8(13):2014-2018.
10. Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene. 2012;31(36):4054-4066.
11. Del Vecchio CA, Giacomini CP, Vogel H, et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2013;32(21):2670-2681.
12. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010;17(1):98-110.
13. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
14. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247-4254.
15. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324-333.
16. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
17. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
18. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011;29(15 Suppl):abstract 2006.